Oka M - Search Results

1

Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis.

Tanahashi H, Yamaguchi K, Kurose K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Oga T, Oka M, Hattori N. Tanahashi H, et al. Among authors: oka m. Respirology. 2023 Apr;28(4):380-388. doi: 10.1111/resp.14425. Epub 2022 Nov 29. Respirology. 2023. PMID: 36446578

2

[Usefulness of fractional exhaled nitric oxide measurement for cough treatment].

Shimizu H, Obase Y, Ikeda M, Kurose K, Abe M, Mouri K, Katoh S, Miyashita N, Kobashi Y, Oka M. Shimizu H, et al. Among authors: oka m. Nihon Kokyuki Gakkai Zasshi. 2011 Mar;49(3):156-60. Nihon Kokyuki Gakkai Zasshi. 2011. PMID: 21485146 Japanese.

3

Outbreak of pertussis in a university laboratory.

Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Kurose K, Oka M. Miyashita N, et al. Among authors: oka m. Intern Med. 2011;50(8):879-85. doi: 10.2169/internalmedicine.50.4768. Epub 2011 Apr 15. Intern Med. 2011. PMID: 21498936 Free article.

4

Stability of sealed-bag samples for off-line measurement of fractional exhaled nitric oxide.

Shimizu H, Obase Y, Ikeda M, Kurose K, Abe M, Mouri K, Katoh S, Miyashita N, Kobashi Y, Oka M. Shimizu H, et al. Among authors: oka m. Ann Allergy Asthma Immunol. 2011 May;106(5):378-80. doi: 10.1016/j.anai.2011.01.010. Epub 2011 Feb 18. Ann Allergy Asthma Immunol. 2011. PMID: 21530868

5

Step-down of budesonide/formoterol in early stages of asthma treatment leads to insufficient anti-inflammatory effect.

Obase Y, Ikeda M, Kurose K, Abe M, Shimizu H, Ohue Y, Mouri K, Katoh S, Kobashi Y, Oka M. Obase Y, et al. Among authors: oka m. J Asthma. 2013 Sep;50(7):718-21. doi: 10.3109/02770903.2013.795588. Epub 2013 Jun 18. J Asthma. 2013. PMID: 23638898 Clinical Trial.

6

[Anti-CCR4 mAb and regulatory T cells].

Kurose K, Ohue Y, Oka M. Kurose K, et al. Among authors: oka m. Gan To Kagaku Ryoho. 2013 Sep;40(9):1150-5. Gan To Kagaku Ryoho. 2013. PMID: 24047773 Japanese.

7

Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.

Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, Fukuda M, Uenaka A, Oka M, Nakayama E. Ohue Y, et al. Among authors: oka m. Clin Cancer Res. 2014 Oct 1;20(19):5052-63. doi: 10.1158/1078-0432.CCR-14-0742. Epub 2014 Aug 14. Clin Cancer Res. 2014. PMID: 25124687

8

Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).

Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, Oka M, Nakayama E. Kurose K, et al. Among authors: oka m. J Thorac Oncol. 2015 Jan;10(1):74-83. doi: 10.1097/JTO.0000000000000364. J Thorac Oncol. 2015. PMID: 25325779 Free article.

9

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.

Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E. Kurose K, et al. Among authors: oka m. Clin Cancer Res. 2015 Oct 1;21(19):4327-36. doi: 10.1158/1078-0432.CCR-15-0357. Clin Cancer Res. 2015. PMID: 26429981 Clinical Trial.

10

Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.

Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M, Nakayama E. Ohue Y, et al. Among authors: oka m. Cancer Immunol Res. 2016 Dec;4(12):1049-1060. doi: 10.1158/2326-6066.CIR-15-0266. Epub 2016 Oct 31. Cancer Immunol Res. 2016. PMID: 27799141

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,305 results

Search Page

Filters